These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31471582)

  • 61. Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.
    Blanden AR; Yu X; Loh SN; Levine AJ; Carpizo DR
    Drug Discov Today; 2015 Nov; 20(11):1391-7. PubMed ID: 26205328
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Rescue of nonsense mutated p53 by readthrough leads to apoptosis in cancers cells].
    Floquet C; Rousset JP; Bidou L
    Med Sci (Paris); 2011; 27(6-7):585-6. PubMed ID: 21718640
    [No Abstract]   [Full Text] [Related]  

  • 63. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.
    Jordan JJ; Inga A; Conway K; Edmiston S; Carey LA; Wu L; Resnick MA
    Mol Cancer Res; 2010 May; 8(5):701-16. PubMed ID: 20407015
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A common gain of function of p53 cancer mutants in inducing genetic instability.
    Liu DP; Song H; Xu Y
    Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
    [TBL] [Abstract][Full Text] [Related]  

  • 65. MicroRNAs in the p53 network: micromanagement of tumour suppression.
    Hermeking H
    Nat Rev Cancer; 2012 Sep; 12(9):613-26. PubMed ID: 22898542
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture.
    Freedman DA; Levine AJ
    Cancer Res; 1999 Jan; 59(1):1-7. PubMed ID: 9892174
    [No Abstract]   [Full Text] [Related]  

  • 67. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis.
    Lu X; Liu DP; Xu Y
    Oncogene; 2013 Jun; 32(23):2900-6. PubMed ID: 22824795
    [TBL] [Abstract][Full Text] [Related]  

  • 68. What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?
    Hayman L; Chaudhry WR; Revin VV; Zhelev N; Bourdon JC
    Expert Rev Mol Diagn; 2019 Feb; 19(2):149-159. PubMed ID: 30582376
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [miR-34s--a tumor suppression protein p53 highly related microRNA].
    Lou WJ; Chen Q; Liu L; Qian C
    Yi Chuan; 2010 May; 32(5):423-30. PubMed ID: 20466628
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical implications of the p53 tumor-suppressor gene.
    Harris CC; Hollstein M
    N Engl J Med; 1993 Oct; 329(18):1318-27. PubMed ID: 8413413
    [No Abstract]   [Full Text] [Related]  

  • 71. Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks.
    Li XL; Jones MF; Subramanian M; Lal A
    FEBS Lett; 2014 Aug; 588(16):2610-5. PubMed ID: 24726728
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Role of the lncRNA-p53 regulatory network in cancer.
    Zhang A; Xu M; Mo YY
    J Mol Cell Biol; 2014 Jun; 6(3):181-91. PubMed ID: 24721780
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SETD1A induced miRNA network suppresses the p53 gene expression module.
    Yae T; Tajima K; Maheswaran S
    Cell Cycle; 2016; 15(4):487-8. PubMed ID: 26865005
    [No Abstract]   [Full Text] [Related]  

  • 74. P53 and prognosis: new insights and further complexity.
    Vousden KH; Prives C
    Cell; 2005 Jan; 120(1):7-10. PubMed ID: 15652475
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [The p53 gene and protein in 2005: new results, promising opportunities].
    Szoke D; Sipos F; Spisák S; Molnár B; Tulassay Z
    Orv Hetil; 2005 Jul; 146(30):1587-94. PubMed ID: 16136736
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
    Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
    Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association between Mutation and Expression of
    Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
    [TBL] [Abstract][Full Text] [Related]  

  • 78. p53 Antibodies in the sera of patients with various types of cancer: a review.
    Soussi T
    Cancer Res; 2000 Apr; 60(7):1777-88. PubMed ID: 10766157
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Tumor suppressor gene p53. Theoretical principles and their significance for pathology].
    Poremba C; Bankfalvi A; Dockhorn-Dworniczak B
    Pathologe; 1996 May; 17(3):181-8. PubMed ID: 8710788
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Targeting the P53 Protein for Cancer Therapies: The Translational Impact of P53 Research.
    Levine AJ
    Cancer Res; 2022 Feb; 82(3):362-364. PubMed ID: 35110395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.